Pinox

Quick links to important sections

Pinox

Method of action: Antihypertensive, Hypotensive

Treatment option: Hypertension

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pinox

Quick Facts

Property Description
Active ingredient Lercanidipine hydrochloride
Form Film-coated tablets
Pharmacological class Calcium Channel Blocker (Dihydropyridine derivative)
Common use Management of elevated blood pressure
Origin Synthetic compound

What is Pinox and its Active Component?

Pinox is a prescription-only medicinal product primarily used for the management of elevated blood pressure, classified as a Calcium Channel Blocker (CCB). Its core component is the active ingredient, Lercanidipine hydrochloride, a vascular-selective calcium antagonist. This substance is a synthetic dihydropyridine derivative and is the sole therapeutic agent in this preparation, defining it as a monotherapy product. Pinox distinguishes itself within the CCB category by offering the convenience of a film-coated tablet designed for oral administration, a preparation favored for sustained daily treatment.

Lercanidipine’s Function and General Purpose

The general purpose of Lercanidipine is to function as an effective antihypertensive agent by relaxing the walls of the arteries. This is achieved through the inhibition of calcium influx into the muscle cells of the blood vessels. Since calcium is essential for contraction, blocking its entry causes the vessels to widen (vasodilate). This action leads to a reduction of peripheral vascular resistance, thereby lowering the overall arterial pressure. This specific action helps reduce the pressure exerted on the arteries. This sustained physiological action functions to manage high blood pressure effectively, which is the functional goal in patient care.

Form and Administration Type of Pinox

Pinox is supplied as a solid, oral dosage form known as a film-coated tablet. The film coating is a critical manufacturing feature, ensuring the stability of the active substance and promoting its consistent release into the body, a key factor for medications requiring sustained therapeutic effects. This preparation style makes the Pinox formulation well-suited for reliable, long-term maintenance treatment.

What side effects are possible with Pinox?

Possible Side Effects and Safety Information

The safety profile of Pinox (Lercanidipine hydrochloride) is officially classified based on the frequency and the physiological system affected, consistent with government regulatory documentation. Adverse reactions are grouped using standardized frequency terminology, such as Common, Uncommon, and Rare events, as established by major regulatory bodies.


Adverse Reaction Classification

Classification Examples of Reactions (Based on Regulatory Documents)
Common (1/100) Headache, Dizziness, Flushing, Peripheral Edema, Tachycardia, Palpitations
Uncommon (1/1,000) Asthenia (fatigue), Nausea, Vomiting, Diarrhea, Rash, Myalgia, Somnolence
Rare (1/10,000) Angina Pectoris, Hypotension, Syncope, Urticaria, Reversible increases in hepatic transaminases

Safety Patterns and Restrictions

Adverse reactions linked to the widening of blood vessels (vasodilation), such as flushing and headache, are often officially noted as being more common at the beginning of treatment or during dose changes. The safety profile also includes explicitly documented serious adverse reactions, such as new onset or exacerbation of Angina Pectoris, Syncope, and Hepatitis, although these are classified as rare.

Safety constraints necessitate that the medicine is contraindicated in certain severe pre-existing conditions. These restrictions include severe hepatic impairment and severe renal impairment (creatinine clearance < 30 mL/min), as well as specific severe cardiovascular conditions like unstable angina pectoris or within one month of a myocardial infarction. Caution is generally advised when used in older adults or individuals with mild to moderate organ impairment.

Overdose and Emergency Response

Overdose and when to seek help: Official regulatory information for Pinox

Overdose Scope

Category Official Regulatory Documentation
Documented overdose presentations Severe hypotension (low blood pressure), reflex tachycardia (fast heartbeat), dizziness, headache, and potential for unconsciousness.
Physiological systems affected Cardiovascular system (circulatory function).
Emergency-response statements Seek immediate medical attention and go to an Emergency Department straight away if more than the prescribed dose is taken.

Overdose Classifications (High-Level)

Category Official Regulatory Documentation
Severity classification Can result in severe, life-threatening profound circulatory collapse, necessitating observation in a high-care setting.
Overdose-context constraints Management is limited to supportive treatment, as no specific antidote is known for Lercanidipine.

Resulting overdose structure

Official overdose statements:

  • Overdose is primarily defined by hemodynamic instability, including excessive hypotension and changes in heart rhythm.
  • Urgent medical help is required following intake of any amount exceeding the prescribed dosage, even without immediate symptoms.
  • Continuous cardiovascular monitoring for at least 24 hours is a required procedural step due to the drug’s prolonged action.
  • Symptomatic and supportive measures are the standard management approach, including the potential administration of intravenous calcium gluconate.

Connection to the overall overdose profile: Regulatory documents strictly define the Pinox overdose profile by the risk of profound cardiovascular instability. Any exposure above the prescribed dosage mandates seeking immediate medical attention due to the severe, documented risk of circulatory failure. Management is officially directed toward structured supportive care in a monitored environment. This approach emphasizes the requirement for expert intervention and the absence of a known specific antidote.

Therapeutic Uses of Pinox

What Pinox Treats: Main Uses and Benefits

Pinox is applied across therapeutic domains where physiological support is needed, helping to address conditions that may become intense or disruptive. This medication is generally relevant for managing vascular resistance and addressing symptoms related to elevated arterial pressure states.

It is relevant for managing physiological factors that interfere with daily health, specifically focused on hypertension and vascular tension. Pinox is commonly used for conditions requiring sustained blood pressure management, often during phases when cardiovascular strain becomes a primary clinical concern. It provides support that helps ease the overall physiological burden on the circulatory system.

Core Therapeutic Focus

Pinox is used for managing conditions that create noticeable physiological strain in situations requiring long-term symptomatic assistance. It is used in clinical scenarios involving chronic or episodic arterial changes.


Quick Facts

  • Relief Focus: Applied when arterial symptoms create noticeable physiological strain.
  • Symptom Scope: Helps address factors related to vascular discomfort and systemic pressure imbalance.
  • Benefit: Provides support that helps ease the overall cardiovascular burden.

Regulatory References

  1. NIH MedlinePlus overview of NSAIDs

Eligibility and Restrictions for Use

Who Can and Cannot Use Pinox?

Pinox (Lercanidipine hydrochloride) is officially designated for use in adults aged 18 years and older for the treatment of essential hypertension. Eligibility is strictly defined by regulatory documentation, which outlines absolute contraindications and populations requiring conditional use.

Contraindicated Populations (Must Not Use)

Use is strictly contraindicated in patients with the following conditions:

  • Severe hepatic impairment or severe renal impairment (GFR < 30 ml/min), including those on dialysis.
  • Untreated congestive cardiac failure, unstable angina pectoris, or a recent myocardial infarction (within one month).
  • Left ventricular outflow tract obstruction.
  • Hypersensitivity to Lercanidipine or any dihydropyridine.
  • Concomitant use with strong CYP3A4 inhibitors (e.g., ciclosporin) or consumption of grapefruit/grapefruit juice.

Age and Developmental Restrictions

  • Children and Adolescents (under 18): Use is not recommended; safety and efficacy have not been established in this age group.
  • Pregnancy and Breastfeeding: Use is contraindicated. Women of child-bearing potential must use effective contraception.

Conditional Use (Requires Special Care)

Use requires special care when commencing treatment in patients with mild to moderate renal dysfunction, mild to moderate hepatic dysfunction, or for elderly patients. The label also advises caution for those with ischaemic heart disease or left ventricular dysfunction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pinox (Lercanidipine) possesses an official interaction profile defined primarily by its metabolism via the CYP3A4 enzyme system and its pharmacodynamic effects. Regulatory documentation classifies the following substances and interactions:

Classification/Entity Official Regulatory Statement
Contraindicated Combinations Strong CYP3A4 inhibitors (e.g., Ketoconazole, Itraconazole, Erythromycin, Clarithromycin), Ciclosporin, and Grapefruit/Grapefruit juice.
Metabolic Basis Pinox is metabolized by the CYP3A4 enzyme. Inhibitors cause a considerable increase in plasma levels (e.g., 15-fold increase in AUC with Ketoconazole); Inducers (e.g., Rifampicin, Carbamazepine) may reduce its antihypertensive effect.
Food/Substance Restriction Grapefruit/Grapefruit juice must not be taken. Alcohol should be avoided due to the potentiation of the vasodilating effect.
Timing Requirements Must be administered in the morning at least 15 minutes before breakfast to mitigate the increased systemic exposure caused by high-fat meals.
Pharmacodynamic Effects Co-administration with Beta-blockers or other antihypertensive agents may result in additive hypotensive effects.
Population Note The antihypertensive effect may be enhanced in moderate hepatic impairment due to increased bioavailability.

Connection to the overall interaction profile

The regulatory documents define the product's interaction structure through its dependence on CYP3A4 metabolic clearance, which dictates formal prohibitions for strong inhibitors and specific foods. This pharmacokinetic constraint is coupled with pharmacodynamic effects that lead to additive blood pressure-lowering activity when combined with other antihypertensive drug classes, alongside mandatory timing rules for ingestion.

Mechanism of Action

Selective Blockade of Vascular L-Type Calcium Channels

This section describes the drug's immediate molecular action: its high-affinity binding to and inhibition of the voltage-dependent L-type calcium channels ( Ca v1.2) found in the walls of the peripheral arteries. This selective interaction prevents the influx of Ca^2+ ions, which are the primary molecular signal required for vascular smooth muscle contraction.

Reduction of Systemic Vascular Resistance

By blocking the calcium signal, Lercanidipine interrupts the excitation-contraction coupling pathway in the arterioles, causing the vessel walls to relax and widen (vasodilation). This sustained widening of the peripheral arterioles directly results in a reduction of the Total Peripheral Resistance (TPR), which is the key physiological mechanism translating molecular action into a systemic change in arterial pressure dynamics.

Sustained Membrane Interaction and Kinetic Advantage

This molecule's high lipophilicity allows it to gradually accumulate and interact with its target from a depot within the cell membrane. This slow and sustained modulation of the calcium channels leads to a gradual onset of the physiological effect, a kinetic property that minimizes the activation of counter-regulatory reflex mechanisms such as reflex tachycardia often triggered by rapid changes in peripheral resistance.

Dosage and Administration Information

How Pinox is Used

Pinox (Lercanidipine hydrochloride) is administered through the oral route as a film-coated tablet, available in 10 mg and 20 mg strengths. The typical usage pattern involves adherence to dosing frequency and timing relative to meals.

Dosage and Administration Timing

The starting dose for adults is typically 10 mg, taken once daily. Based on clinical requirements, this may be gradually increased to the standard maintenance dose of 20 mg once per day. An established principle of use is that the tablet is ingested at least 15 minutes before a meal, preferably in the morning, and swallowed whole with sufficient fluid. This timing is intended to ensure consistent systemic availability.

Titration and Special Use

Dose adjustments, such as increasing from 10 mg to 20 mg, are performed gradually because the maximal physiological effect of a dose may take approximately two weeks to fully manifest. Furthermore, the ingestion of grapefruit or grapefruit juice is a procedural restriction and is avoided during the duration of use.

Regarding specific populations, no routine daily dosage adjustment is specified for older adults, although care is typically observed upon initiation. For individuals with mild-to-moderate hepatic or renal impairment, caution is exercised when increasing the dose to 20 mg. The medicine is not recommended for use in children under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pinox

Evidence for Use in Essential Hypertension

The evidence for Pinox (Lercanidipine) is built upon numerous Randomized Controlled Trials (RCTs), a common methodology in clinical research. These studies were designed to explore whether Lercanidipine was associated with changes in blood pressure measurements. Many trials were double-blind, ensuring neither participants nor researchers knew who received the medicine or a comparison treatment. This foundation of RCTs is supported by meta-analyses that combine data from multiple, separate trials to explore patterns across research.

Research contexts applied in studies examining elevated blood pressure in adults with essential hypertension. Findings describe patterns observed, reporting how blood pressure levels evolved in the observed populations during the trial periods. Research recorded changes in both Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP), which are the primary endpoints used in regulatory evidence.


Study Focus: Outcomes and Comparators

Studies explored how the medicine compared to other treatments. Research examined Pinox against an inactive substance (placebo) to explore differences in measured blood pressure changes. Comparative trials were also conducted, where Pinox was observed against other classes of medication studied for blood pressure management.

Outcomes that were monitored included whether patients reached specific target blood pressure goals set by the researchers, known as BP normalization rates. Furthermore, some studies examined the use of Pinox as a component of combination therapy alongside another blood pressure medicine.


Research Gaps and Areas of Uncertainty

Most core trials used to establish initial evidence focused on short-term follow-up, observing participants for four to twelve weeks. These intervals were used to study patterns related to initial changes in blood pressure. While blood pressure reduction was documented, the evidence base relies heavily on surrogate endpoints.

Findings related to long-term effects are not fully established by prospective, randomized studies. Data for certain groups, such as pediatric populations, remain insufficient, and research is not widely available to characterize use during pregnancy. Comparative evidence that consistently defines its long-term pattern against other blood pressure medication remains limited. Research does not determine whether an individual will respond similarly over a lifetime.

Key Studies & References

  1. Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension | ClinicalTrials.gov (Example of RCT structure and endpoints)
  2. Public Assessment Report - Lercanidipine HCl Mylan 10 mg and 20 mg (European Medicines Agency document used for regulatory context and general evidence base)

Frequently Asked Questions (FAQ)

Common questions about Pinox (FAQ)

Q: Are the common side effects of Pinox generally considered mild?

Official product information indicates that common adverse reactions linked to Pinox, such as headache, flushing, and swelling of the ankles, are generally reported as mild to moderate in intensity. These effects often lessen or resolve during the first few weeks of treatment.

Q: What signs might indicate an allergic reaction to Pinox, based on official information?

Signs of a serious allergic reaction may include a rash, itching, or hives on the skin, or they can progress to more serious symptoms like wheezing or tightness in the chest or throat. Patients should immediately inform their healthcare provider if these signs occur.

Q: Can herbal supplements affect how Pinox is processed by the body?

Yes, Pinox is metabolized by the CYP3A4 enzyme system. Products that either inhibit or induce this enzyme, including certain herbal supplements, can significantly change the medicine's level in the bloodstream, altering its intended effect. The prescribing healthcare provider should be aware of all supplements being used.

Q: Do official sources list interactions between Pinox and common prescription medications?

Regulatory documents list interactions with strong CYP3A4 inhibitors and inducers, as well as specific food components like grapefruit. Additionally, combining Pinox with other blood pressure medicines, such as Beta-blockers, can result in additive blood pressure-lowering effects.

Q: How long does it usually take before a patient may notice any effect from Pinox?

Pinox begins to work on the day you start taking it. However, because the dose may require gradual adjustment, the maximal therapeutic effect that lowers blood pressure may take approximately two weeks to fully appear.

Q: What is the difference between the brand name Pinox and a generic version of the drug?

Pinox is the brand name given to the medicine, whose active ingredient is Lercanidipine hydrochloride. A generic version would contain the same active ingredient and serve as a pharmaceutical equivalent to the brand product.

Q: Is Pinox a new type of drug, or is it similar to older treatments?

Pinox is classified as a dihydropyridine calcium channel blocker. While it belongs to the same class as older treatments, its specific composition is associated with a slow onset of action that is designed to help minimize the reflex increase in heart rate often seen with faster-acting agents.

Q: What kind of general expectations should a patient have about Pinox's effects?

Since high blood pressure often has no noticeable symptoms, a patient may not feel any different when taking Pinox. The effectiveness of the medicine is verified by regular blood pressure checks performed by a healthcare professional.

Q: Does Pinox have different known side effects in older adults compared to younger people?

Official documents state that no routine adjustment of the daily dose is typically required for older adults. However, special care is required by the prescribing healthcare provider when initiating treatment or increasing the dose.

Q: What is the general guidance if a person misses a single dose of Pinox?

If a dose is forgotten, official guidance is to skip the missed dose entirely and take the next dose at the usual scheduled time. Official guidance emphasizes that a double dose must not be taken to make up for the missed one.

Q: How is the duration of Pinox's effect generally described in official labeling?

Pinox is designed for once-daily dosing. Its specific interaction with lipid membranes helps the medicine maintain its blood pressure-lowering activity for a prolonged period, typically supporting continuous coverage for up to 24 hours.

Q: Is there a known 'rebound effect' mentioned in official documents if Pinox is discontinued?

Regulatory documents warn that stopping Pinox abruptly may cause blood pressure to rise, which increases the risk of serious cardiac events. Discontinuation of this medicine must only be performed under the guidance of a healthcare provider.

Q: What is the current status of research into Pinox's potential use in other conditions?

The established evidence for Pinox is specifically for essential hypertension in adults. Data on its use during pregnancy and in pediatric populations is currently insufficient, and its use in these groups is generally contraindicated by regulatory bodies.

Q: Is Pinox the same as another commonly compared medicine?

No, Pinox is not the same as other medications, but it is classified in the same group of medicines known as dihydropyridine calcium channel blockers. This class includes other agents such as nifedipine and amlodipine.

Q: Does Pinox require any special medical monitoring or regular lab tests?

While routine monitoring is not mandated for all users, careful monitoring is required for patients with mild-to-moderate liver or kidney impairment. Additionally, blood pressure monitoring is generally advised when taking this type of medicine.

Q: Why is Pinox only available by prescription from a healthcare provider?

Pinox is a prescription-only medicine because it is used to treat the serious condition of high blood pressure, which requires professional diagnosis, supervision, and ongoing monitoring to ensure proper use, manage potential risks, and optimize effectiveness.

Q: Is Pinox considered a controlled substance in the United States?

No, Pinox (Lercanidipine) is not marketed in the United States and is not classified as a controlled substance under the US Controlled Substances Act.

Q: Does Pinox carry any warnings related to operating machinery or driving?

Yes. Official patient information indicates that Pinox may cause side effects such as dizziness, somnolence (drowsiness), or asthenia (fatigue). Official patient information advises against driving or operating machinery if these effects occur.

How should Pinox be stored and disposed of?

How to Store and Dispose of Pinox?

Storage and Disposal Requirement Official Regulatory Statement
Temperature & Protection Store at a temperature below 30 C (86 F). Do not freeze.
Container & Handling Keep the product in its original container and keep the container tightly closed to protect the tablets from moisture.
Child Safety Keep out of the sight and reach of children.
Disposal Dispose of unused product according to local requirements.
Environmental Restriction Do not dispose of the product via household waste or by pouring it into a wastewater system (sewer or toilet).

Regulatory documentation defines how Pinox must be stored, mandating a maximum temperature of 30 C and requiring protection from moisture by keeping the original container tightly closed. The product must be stored in a manner that prevents access by children. Disposal must adhere to local regulations for pharmaceutical waste, with an explicit prohibition against flushing the product or discarding it in standard household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pinox found in:

A-Z Index: